Antiviral Drugs: From Basic Discovery through Clinical Trials

Antiviral Drugs: From Basic Discovery through Clinical Trials

Editor(s): Wieslaw M. Kazmierski

Published Online: 20 JUN 2011 08:42AM EST

Print ISBN: 9780470455630

Online ISBN: 9780470929353

DOI: 10.1002/9780470929353

About this Book

This book focuses on new small molecule approaches to combat viral infections. The chapters describe the discovery and development from bench through the clinic of relatively recently-approved antiviral drugs and compounds in advanced clinical development. Organized by a virus (such as HIV, HCV, RSV, influenza, HBV and CMV) and written by top academic and industrial authorities in the field, the book provides a unique opportunity to study, understand and apply discovery and development principles and learning without the need for an individual to research, analyze and synthesize all immense sourcing references.  Topics showcase challenges and solutions of issues encountered, offering tremendous experience accumulated over many years of research that will be particularly useful to basic and bench scientists as well as clinicians as they continue discovering and developing new drugs and therapies.

Table of contents

    1. You have free access to this content
    1. You have free access to this content
  1. Part I: Human Immunodeficiency Virus - Section I: HIV Protease Inhibitors

    1. Chapter 3

      Darunavir (Prezista, TMC114): From Bench to Clinic, Improving Treatment Options for HIV-Infected Patients (pages 31–45)

      Marie-Pierre de Béthune, Vanitha Sekar, Sabrina Spinosa-Guzman, Marc Vanstockem, Sandra De Meyer, Piet Wigerinck and Eric Lefebvre

  2. Part I: Human Immunodeficiency Virus - Section II: HIV Non-nucleoside Reverse Transcriptase Inhibitors

    1. Chapter 6

      Etravirine: From TMC125 to Intelence: A Treatment Paradigm Shift for HIV-Infected Patients (pages 71–84)

      Koen Andries, Ann Debunne, Thomas N. Kakuda, Michael Kukla, Ruud Leemans, Johan Vingerhoets, Brian Woodfall and Marie-Pierre de Béthune

  3. Part I: Human Immunodeficiency Virus - Section III: HIV Nucleoside Reverse Transcriptase Inhibitors

  4. Part I: Human Immunodeficiency Virus - Section IV: HIV Entry Inhibitors

    1. Chapter 11

      Discovery and Development of HIV-1 Entry Inhibitors That Target gp120 (pages 149–162)

      John F. Kadow, John Bender, Alicia Regueiro-Ren, Yasutsugu Ueda, Tao Wang, Kap-Sun Yeung and Nicholas A. Meanwell

  5. Part I: Human Immunodeficiency Virus - Section V: HIV Integrase Inhibitors

  6. Part II: Hepatitis C Virus - Section VI: Protease Inhibitors

    1. Chapter 15

      Discovery and Development of Telaprevir (pages 207–224)

      Anne-Laure Grillot, Luc J. Farmer, B. Govinda Rao, William P. Taylor, Ilan S. Weisberg, Ira M. Jacobson, Robert B. Perni and Ann D. Kwong

    2. Chapter 19

      Discovery and Development of the HCV Protease Inhibitor TMC435 (pages 273–286)

      Pierre Raboisson, Gregory Fanning, Herman de Kock, Åsa Rosenquist, René Verloes and Kenneth Simmen

  7. Part II: Hepatitis C Virus - Section VII: HCV Polymerase Nucleoside Inhibitors

  8. Part II: Hepatitis C Virus - Section VIII: Other HCV Inhibitors

    1. Chapter 23

      HCV Viral Entry Inhibitors (pages 329–337)

      Flossie Wong-Staal, Guohong Liu and Jeffrey McKelvy

  9. Part III: Respiratory Syncytial Virus Inhibitors

    1. Chapter 24

      Discovery of the RSV Inhibitor TMC353121 (pages 339–352)

      Jean-François Bonfanti, Gabriela Ispas, Frans Van Velsen, Wieslawa Olszewska, Tom Gevers and Dirk Roymans

  10. Part IV: Influenza, Hepatitis B, and Cytomegalovirus Inhibitors

    1. Chapter 28

      Discovery and Development of Entecavir (pages 401–416)

      Richard Wilber, Bruce Kreter, Marc Bifano, Stephanie Danetz, Lois Lehman-McKeeman, Daniel J. Tenney, Nicholas Meanwell, Robert Zahler and Helena Brett-Smith

    1. You have free access to this content

SEARCH